B-CELL LYMPHOMA

This early-phase study tests whether combining two drugs, venetoclax and inotuzumab ozogamicin, is safe and effective for people with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. About 23 adults with CD22-positive B-ALL will receiv…

This study tests whether the drug anakinra can prevent or reverse severe side effects from CAR-T cell therapy, a treatment for certain blood cancers. About 62 adults with relapsed B-cell cancers will receive anakinra alongside their CAR-T treatment. The goal is to reduce serious …

This study tested whether the drug glofitamab could stop large B-cell lymphoma from coming back in patients who had achieved complete remission but still had tiny amounts of cancer detectable (minimal residual disease). The trial was withdrawn before enrolling any participants, s…

This early-phase study tests a "universal" CAR-T cell therapy (UWD-CD19) for people with B-cell lymphoma or leukemia that has not responded to standard treatments. About 30 participants will receive a single infusion of these engineered immune cells after a short chemotherapy cou…

This study looks at the long-term safety of the drug pirtobrutinib in people with certain blood cancers, like chronic lymphocytic leukemia or non-Hodgkin lymphoma. Participants must have already completed an earlier study and still benefit from the drug. They receive treatment ev…

This early-phase trial tests a new drug, loncastuximab tesirine, combined with standard chemotherapy (DA-EPOCH-R) in 11 adults with aggressive B-cell lymphoma. The goal is to find the safest dose and see if the combination can control the disease. Participants must have certain t…

This early-phase study tests a new approach for people with B-cell lymphoma or leukemia that has returned or not responded to standard therapy. Researchers take a patient's own immune cells (T cells), modify them in the lab to recognize and attack cancer cells carrying the CD19 p…

This study tests a combination of two targeted drugs, palbociclib and ibrutinib, in people with mantle cell lymphoma that has been treated before but returned. The goal is to see if the combination can control the cancer for longer. About 39 adults will take the drugs in 28-day c…

This early-stage study tests an experimental pill called LOXO-338 in people with advanced blood cancers (like certain leukemias, lymphomas, and multiple myeloma) who have already tried standard treatments. The main goals are to find the safest dose and to see if the drug can shri…

This early-phase study tests a new type of immunotherapy called tri-specific CAR T-cells for people with B-cell lymphomas that have come back or not responded to treatment. The therapy is designed to target three different markers on cancer cells to improve effectiveness and redu…

This study tracks 150 people who previously received Caribou cell therapy for blood cancers like lymphoma or leukemia. The goal is to watch for long-term side effects and safety issues over 15 years. No new treatment is given—just regular check-ups to see how patients are doing.…

This study looks at whether a blood test (liquid biopsy) can predict if lymphoma will come back within 1-2 years after finishing first treatment. It involves 108 adults with B-cell or Hodgkin lymphoma. The goal is to see if this test works as well as or better than the standard P…

This study follows people who previously received an experimental CAR-T cell therapy from AvenCell for cancers like lymphoma, leukemia, or prostate cancer. The goal is to track long-term side effects, including new cancers, nerve problems, or immune disorders. About 178 participa…